BlueRock Therapeutics LP

In News

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease - Bayer

Bayer - Oct 07, 2025

FDA grants Orphan Drug designation to BlueRock's RP cell therapy - Eyes On Eyecare

Eyes On Eyecare - Jan 23, 2026

36-Month Phase I: BlueRock’s bemdaneprocel Shows Durable Safety and Motor Improvements - Stock Titan

Stock Titan - Oct 07, 2025

First-in-Human Trial of OpCT-001: An iPSC-Derived Cell Therapy for Primary Photoreceptor Diseases - BioInformant

BioInformant - Jul 25, 2025

BlueRock Therapeutics announces publication in Nature of - GlobeNewswire

GlobeNewswire - Apr 16, 2025

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan - Bayer

Bayer - Dec 17, 2025

Forging the future of cell therapy: Bayer and BlueRock’s unique journey - Fierce Biotech

Fierce Biotech - Jun 02, 2025

BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial - PR Newswire

PR Newswire - Mar 14, 2023

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel - Bayer

Bayer - Sep 22, 2025

Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs - Fierce Biotech

Fierce Biotech - Jun 25, 2025

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel - CGTLive®

CGTLive® - Jul 22, 2024

Bluerock Therapeutics’ new cell therapy product shows promise for the treatment of Parkinson’s disease - BioWorld MedTech

BioWorld MedTech - Jun 19, 2023

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment